Figure 6.
Dihydromyricetin (DHM) decreases Aβ levels in APP/PS1 mice. A, ELISA quantification of Aβ1‐40 was performed in APP/PS1 mice. Aβ1‐40 levels were markedly decreased after DHM treatment. Values are presented as mean ± SEM (*P < .05 in the 2‐week group, **P < .01 in the 4‐week group vs control groups). B, ELISA quantification of Aβ1‐42 was performed in APP/PS1 mice (*P < .05 in the 2‐week group, ***P < .001 in the 4‐week group vs control groups). C, Western blot analysis showing no significant differences in expression levels of APP and BACE1 between control and DHM‐treated groups at 2 weeks or 4 weeks